Great Lakes Advisors’s Acadia Pharmaceuticals ACAD Stock Holding History
Bought
Maintained
Sold
Other funds holding ACAD
BBA
Great Lakes Advisors's ACAD Position: Q3 2026 in Review
Great Lakes Advisors reduced its Acadia Pharmaceuticals (ACAD) stake by 65% in Q3 2026, selling an estimated $2.65M and leaving 52,651 shares worth $1.06M. The position accounts for 0.01% of the portfolio, ranked #470.
Great Lakes Advisors first reported a position in ACAD in Q2 2018 and has held it in 12 quarters since. The position peaked at $24.1M in Q4 2020. 351 funds tracked by Wall St. Rank hold ACAD as of Q3 2026.
- Great Lakes Advisors held 52,651 shares of Acadia Pharmaceuticals worth $1.06M as of Q3 2026.
- Great Lakes Advisors sold 98,690 Acadia Pharmaceuticals shares in Q3 2026, an estimated $2.65M.
- Acadia Pharmaceuticals made up 0.01% of Great Lakes Advisors's portfolio in Q3 2026, its #470 holding.
- Great Lakes Advisors first reported a position in Acadia Pharmaceuticals in Q2 2018 and has held it in 12 quarters since.
- Great Lakes Advisors's Acadia Pharmaceuticals position peaked at $24.1M in Q4 2020.
- 351 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2026.
Based on Great Lakes Advisors's 13F filing for Q3 2026, filed 6 Nov 2026.